Abstract
As our understanding of T-cell activation has increased at the molecular level, several investigators have begun to discuss the idea of using synthetic peptides as vaccines for inducing T-cell immunity (LERNER 1984; LAVER and AIR 1985). My view as to the value of such an approach is rather pessimistic. In this paper I will briefly outline our current understanding of antigen recognition by T cells and then discuss in detail what I see to be the major pitfalls in the peptide approach to Vaccine development. I do not mean to imply in this discussion that developing vaccines to induce T-cell immunity represents a fruitless endeavor. Rather, I wish to stress that the synthetic peptide approach may not be the most rational one to choose or the most cost-effective at the present time.KeywordsMajor Histocompatibility ComplexSynthetic PeptideAllelic FormMajor Histocompatibility Complex HaplotypeHelper DeterminantThese keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
